Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes

References

• Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. 2021;10:117. doi:10.3390/cells10010117
   PubMed Web of Science ®Google Scholar
• Santos FP, Kantarjian H, Quintás-Cardama A, Cortes J. Evolution of therapies for chronic myelogenous leukemia. Cancer J. 2011;17:465–476. doi:10.1097/PPO.0b013e31823dec8d
   PubMed Web of Science ®Google Scholar
• Isfort S, Brümmendorf TH. Bosutinib in chronic myeloid leukemia: patient selection and perspectives. J Blood Med. 2018;9:43–50. doi:10.2147/JBM.S129821
   PubMed Web of Science ®Google Scholar
• Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–e193. doi:10.1016/S2352-3026(15)00048-4
   PubMed Web of Science ®Google Scholar
• Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–2857. doi:10.1200/JCO.2015.66.2866
   PubMed Web of Science ®Google Scholar
• Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133:2374–2384. doi:10.1182/blood.2018882233
   PubMed Web of Science ®Google Scholar
• Atallah E, Sweet K. Treatment-free remission: the new goal in CML therapy. Curr Hematol Malig Rep. 2021;16:433–439. doi:10.1007/s11899-021-00653-1
   PubMed Web of Science ®Google Scholar
• Ciftciler R, Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur Rev Med Pharmacol Sci. 2021;25:7787–7798. doi:10.26355/eurrev_202112_27625
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Binotto G, Capodanno I, et al. Making treatment-free remission (TFR) easier in chronic myeloid leukemia: fact-checking and practical management tools. Target Oncol. 2021;16:823–838. doi:10.1007/s11523-021-00831-4
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Gambacorti-Passerini C, Abboud C, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the Phase 4 BYOND study. Leukemia. 2020;34:2125–2137. doi:10.1038/s41375-020-0915-9
   PubMed Web of Science ®Google Scholar
• Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91:869–874. doi:10.1002/ajh.24423
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927. doi:10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–2340. doi:10.1200/JCO.2015.64.8899
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Rosti G, Cross NC, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30:57–64. doi:10.1038/leu.2015.270
   PubMed Web of Science ®Google Scholar
• Deeks ED. Asciminib: first approval. Drugs. 2022;82:219–226. doi:10.1007/s40265-021-01662-3
   PubMed Web of Science ®Google Scholar
• Asciminib moves toward EU approval for Ph+ CML in chronic phase. Available from: https://www.onclive.com/view/asciminib-moves-toward-eu-approval-for-ph-cml-in-chronic-phase. Accessed November 21, 2022.
   Google Scholar
• Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458. doi:10.1016/j.leukres.2020.106458
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hughes TP, Larson RA, et al. Correction to: long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:2142–2143. doi:10.1038/s41375-021-01306-1
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404. doi:10.1182/blood-2016-09-739086
   PubMed Web of Science ®Google Scholar
• Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44. doi:10.1186/s13045-021-01055-9
   PubMed Web of Science ®Google Scholar
• Bosi GR, Fogliatto LM, Costa TE, et al. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials? Hematol Transfus Cell Ther. 2019;41:222–228. doi:10.1016/j.htct.2018.11.005
   PubMedGoogle Scholar
• Loscocco F, Visani G, Galimberti S, Curti A, Isidori A. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol. 2019;9:939. doi:10.3389/fonc.2019.00939
   PubMed Web of Science ®Google Scholar
• Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013;4:103–117. doi:10.1177/2040620712468289
   PubMedGoogle Scholar
• Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007;:371–375. doi:10.1182/asheducation-2007.1.371
   PubMedGoogle Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417. doi:10.1056/NEJMoa062867
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–1054. doi:10.1038/leu.2016.5
   PubMed Web of Science ®Google Scholar
• Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): final 5-year results from the BFORE trial. Blood. 2020;136:41–42. doi:10.1182/blood-2020-137393
   Web of Science ®Google Scholar
• Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011;25:981–995. doi:10.1016/j.hoc.2011.09.004
   PubMed Web of Science ®Google Scholar
• Zhang WW, Cortes JE, Yao H, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009;27:3642–3649. doi:10.1200/JCO.2008.19.4076
   PubMed Web of Science ®Google Scholar
• Patel AB, O’Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31:589–612. doi:10.1016/j.hoc.2017.04.007
   PubMed Web of Science ®Google Scholar
• Alves R, Gonçalves AC, Rutella S, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers (Basel). 2021;13:4820. doi:10.3390/cancers13194820
   PubMed Web of Science ®Google Scholar
• Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38:10–20. doi:10.1016/j.leukres.2013.09.011
   PubMed Web of Science ®Google Scholar
• Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36:1825–1833. doi:10.1038/s41375-022-01589-y
   PubMed Web of Science ®Google Scholar
• Liu J, Yang H, Xu X, Yi S, Meng L. Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis. Oncol Lett. 2020;20:1071–1076. doi:10.3892/ol.2020.11650
   PubMed Web of Science ®Google Scholar
• Dhillon S. Olverembatinib: first approval. Drugs. 2022;82:469–475. doi:10.1007/s40265-022-01680-9
   PubMed Web of Science ®Google Scholar
• Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15:113. doi:10.1186/s13045-022-01334-z
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Cortes JE, Zyczynski T, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019;94:46–54. doi:10.1002/ajh.25306
   PubMed Web of Science ®Google Scholar
• Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2016;2016:170–179. doi:10.1182/asheducation-2016.1.170
   PubMedGoogle Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–1671. doi:10.1038/leu.2016.104
   PubMed Web of Science ®Google Scholar
• Mohanavelu P, Mutnick M, Mehra N, et al. Meta-analysis of gastrointestinal adverse events from tyrosine kinase inhibitors for chronic myeloid leukemia. Cancers (Basel). 2021;13:1643. doi:10.3390/cancers13071643
   PubMed Web of Science ®Google Scholar
• Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel). 2020;12:826. doi:10.3390/cancers12040826
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Chronic Myeloid Leukemia. V1; 2023.
   Google Scholar
• Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107–112. doi:10.1038/leu.2012.181
   PubMed Web of Science ®Google Scholar
• Cortes J, Brümmendorf TH, Goh YT, et al. Bosutinib for chronic phase chronic myeloid leukemia after imatinib failure: >8-year update of a phase 1/2 study. Presented at: 25th European Hematology Association Annual Congress (EHA25 Virtual); 2020.
   Google Scholar
• Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042–2050. doi:10.1182/blood.2021012082
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Brümmendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol. 2014;89:732–742. doi:10.1002/ajh.23728
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95:232–240. doi:10.3324/haematol.2009.011452
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141–1145. doi:10.1182/blood-2010-03-277152
   PubMed Web of Science ®Google Scholar
• Carofiglio F, Lopalco A, Lopedota A, et al. Bcr-Abl tyrosine kinase inhibitors in the treatment of pediatric CML. Int J Mol Sci. 2020;21:4469. doi:10.3390/ijms21124469
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety and efficacy of ponatinib for treatment of pediatric recurrent or refractory leukemias, lymphomas or solid tumors. Available from: https://ClinicalTrials.gov/show/NCT03934372. Accessed February 21, 2023.
   Google Scholar
• Athale U, Hijiya N, Patterson BC, et al. Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children’s Oncology Group CML Working Group. Pediatr Blood Cancer. 2019;66:e27827. doi:10.1002/pbc.27827
   PubMed Web of Science ®Google Scholar
• Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120–8135. doi:10.1021/acs.jmedchem.8b01040
   PubMed Web of Science ®Google Scholar
• Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal. 2010;3:re6. doi:10.1126/scisignal.3139re6
   PubMed Web of Science ®Google Scholar
• Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer. 2012;3:436–446. doi:10.1177/1947601912458584
   PubMedGoogle Scholar
• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–2326. doi:10.1056/NEJMoa1902328
   PubMed Web of Science ®Google Scholar
• Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15:1406–1416. doi:10.1111/cts.13252
   PubMed Web of Science ®Google Scholar
• SCEMBLIX (asciminib). Prescribing information. Novartis; 2021.
   Google Scholar
• Rea D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031–2041. doi:10.1182/blood.2020009984
   PubMed Web of Science ®Google Scholar
• Hughes T, Mauro MJ, Kim D, et al. Asciminib in heavily pretreated patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) sensitive to tyrosine kinase inhibitor (TKI) therapy. Presented at: EHA25 Virtual Congress; 2020.
   Google Scholar
• Mauro MJ, Hughes T, Kim D, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37:1048–1059. doi:10.1038/s41375-023-01860-w
   PubMed Web of Science ®Google Scholar
• Hughes T, Cortes J, Rea D, et al. Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial. Presented at: EHA2022 Hybrid Congress; Vienna, Austria; 2022.
   Google Scholar
• Hochhaus A, Rea D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617–626. doi:10.1038/s41375-023-01829-9
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of efficacy of CML-CP patients treated with ABL001 versus bosutinib, previously treated with 2 or more TKIs. Available from: https://ClinicalTrials.gov/show/NCT03106779. Accessed February 21, 2023.
   Google Scholar
• Rea D, Mauro MJ, Hochhaus A, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: week 96 update. Presented at: ASCO2022; Chicago, IL; 2022.
   Google Scholar
• Rea D, Hochhaus A, Mauro MJ, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: week 96 update. Presented at: EHA2022; Vienna, Austria; 2022.
   Google Scholar
• Mauro MJ, Boquimpani C, Rea D, et al. CML-417: ASCEMBL phase 3 health-related quality of life (HRQL) comparison of asciminib and bosutinib for patients with chronic myelogenous leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors (TKI). Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 1):S336. doi:10.1016/S2152-2650(21)01785-7
   Google Scholar
• ClinicalTrials.gov. ABL001 for the treatment of chronic myeloid leukemia in patients who are on therapy with tyrosine kinase inhibitor. Available from: https://ClinicalTrials.gov/show/NCT04216563. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Asciminib in monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I mutation. Available from: https://ClinicalTrials.gov/show/NCT04666259. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Study of efficacy and safety of CML-CP patients treated with asciminib versus best available therapy, previously treated with 2 or more tyrosine kinase inhibitors. Available from: https://ClinicalTrials.gov/show/NCT04795427. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. A phase I study of oral ABL001 in patients with CML or Ph+ ALL. Available from: https://ClinicalTrials.gov/show/NCT02081378. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Asciminib treatment optimization in ≥ 3rd line CML-CP. Available from: https://ClinicalTrials.gov/show/NCT04948333. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia. Available from: https://ClinicalTrials.gov/show/NCT04925479. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Asciminib monotherapy, with dose escalation, for 2nd line chronic myelogenous leukemia. Available from: https://ClinicalTrials.gov/show/NCT05384587. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Study of efficacy and safety of asciminib in combination with imatinib in patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Available from: https://ClinicalTrials.gov/show/NCT03578367. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Treatment free remission after combination therapy with asciminib (ABL001) plus imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation. Available from: https://ClinicalTrials.gov/show/NCT04838041. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Asciminib used in consolidation with imatinib vs. imatinib to achieve TFR in CP-CML. Available from: https://ClinicalTrials.gov/show/NCT05413915. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Frontline asciminib combination in chronic phase CML. Available from: https://ClinicalTrials.gov/show/NCT03906292. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. A study of oral asciminib versus other TKIs in adult patients with newly diagnosed Ph+ CML-CP. Available from: https://ClinicalTrials.gov/show/NCT04971226. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. A study to investigate tolerability and efficacy of asciminib (oral) versus nilotinib (oral) in adult participants (≥18 years of age) with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (Ph+ CML-CP) (ASC4START). Available from: https://ClinicalTrials.gov/show/NCT05456191. Accessed February 21, 2023.
   Google Scholar
• ClinicalTrials.gov. Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase. Available from: https://ClinicalTrials.gov/show/NCT05143840. Accessed February 21, 2023.
   Google Scholar
• Sasaki K, Mauro M, Levy MY, et al. ASC2ESCALATE: a phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) previously treated with 1 prior Tyrosine Kinase Inhibitor (TKI). Blood. 2022;140(1):6784–6786. doi:10.1182/blood-2022-167044
   Google Scholar
• Mu H, Zhu X, Jia H, et al. Combination therapies in chronic myeloid leukemia for potential treatment-free remission: focus on leukemia stem cells and immune modulation. Front Oncol. 2021;11:643382. doi:10.3389/fonc.2021.643382
   PubMed Web of Science ®Google Scholar
• Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36:431–443.e5. doi:10.1016/j.ccell.2019.08.004
   PubMed Web of Science ®Google Scholar
• Lindström HJG, Friedman R. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib. BMC Cancer. 2020;20:397. doi:10.1186/s12885-020-06782-9
   PubMed Web of Science ®Google Scholar
• Cortes J, Lang F, Kim D, et al. Combination therapy using asciminib plus imatinib (IMA) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. Presented at: EHA24; Amsterdam, The Netherlands; 2019.
   Google Scholar
• Hijiya N, Maschan A, Rizzari C, et al. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019;134:2036–2045. doi:10.1182/blood.2019000069
   PubMed Web of Science ®Google Scholar
• Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392–399. doi:10.1182/blood-2015-06-648667
   PubMed Web of Science ®Google Scholar
• Nishiyama-Fujita Y, Nakazato T, Iriyama N, et al. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Ann Med. 2022;54:1244–1254. doi:10.1080/07853890.2022.2069280
   PubMed Web of Science ®Google Scholar
• Ford M, Mauro M, Aftandilian C, Sakamoto KM, Hijiya N. Management of chronic myeloid leukemia in children and young adults. Curr Hematol Malig Rep. 2022;17:121–126. doi:10.1007/s11899-022-00673-5
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Shan J, et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012;97:1029–1035. doi:10.3324/haematol.2011.056721
   PubMed Web of Science ®Google Scholar
• Lipton JH, Bryden P, Sidhu MK, et al. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res. 2015;39:58–64. doi:10.1016/j.leukres.2014.10.005
   PubMed Web of Science ®Google Scholar
• Ono T. Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Cancers (Basel). 2021;13:5116. doi:10.3390/cancers13205116
   PubMed Web of Science ®Google Scholar
• Hughes T, Rea D, Boquimpani C, et al. Dynamics of response and response factors in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase 3 ASCEMBL study. Blood. 2022;140(Suppl 1):6757–6759. doi:10.1182/blood-2022-169110
   Google Scholar
• Luna A, Pérez-Lamas L, Boque C, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022;101:2263–2270. doi:10.1007/s00277-022-04932-6
   PubMed Web of Science ®Google Scholar
• Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293–303. doi:10.2147/VHRM.S108874
   PubMed Web of Science ®Google Scholar
• Baggio D, Tan S, Porch K, Shortt J, Ko B. Prediction of cardiovascular events in patients with chronic myeloid leukaemia using baseline risk factors and coronary artery calcium scoring. Intern Med J. 2021;51:1736–1740. doi:10.1111/imj.15517
   PubMed Web of Science ®Google Scholar
• Cortes J. How to manage CML patients with comorbidities. Hematology Am Soc Hematol Educ Program. 2020;2020:237–242. doi:10.1182/hematology.2020006911
   PubMedGoogle Scholar
• Coutinho AD, Makenbaeva D, Farrelly E, Landsman-Blumberg PB, Lenihan D. Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States. Clin Lymphoma Myeloma Leuk. 2017;17(10):676–683. doi:10.1016/j.clml.2017.06.011
   PubMed Web of Science ®Google Scholar
• ICLUSIG (ponatinib). Prescribing information. Takeda; 2022.
   Google Scholar
• TASIGNA (nilotinib). Prescribing information. Novartis; 2021.
   Google Scholar
• Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–453. doi:10.1038/s41375-020-01111-2
   PubMed Web of Science ®Google Scholar
• Lee PM, Chang CT, Yusoff ZM. Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital. Int J Clin Pharm. 2021;43:46–54. doi:10.1007/s11096-020-01070-9
   PubMed Web of Science ®Google Scholar
• Tan BK, Bee PC, Chua SS, Chen LC. Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review. Patient Prefer Adherence. 2021;15:2563–2575. doi:10.2147/PPA.S269355
   PubMed Web of Science ®Google Scholar
• Guerin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30(11):2317–2328. doi:10.1185/03007995.2014.944973
   PubMed Web of Science ®Google Scholar
• Saydam G, Ali R, Demir AM, et al. The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Int J Hematol Oncol. 2022;11(1):IJH38. doi:10.2217/ijh-2021-0010
   PubMedGoogle Scholar
• Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on national comprehensive network treatment guidelines. Clin Lymphoma Myeloma Leuk. 2015;15(12):797–802. doi:10.1016/j.clml.2015.09.008
   PubMed Web of Science ®Google Scholar
• Chow EJ, Doody DR, Wilkes JJ, et al. Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Leuk Lymphoma. 2021;62:1203–1210. doi:10.1080/10428194.2020.1855340
   PubMed Web of Science ®Google Scholar
• Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136:2507–2512. doi:10.1182/blood.2020006911
   PubMed Web of Science ®Google Scholar
• Flynn KE, Atallah E. Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11:80–85. doi:10.1007/s11899-016-0306-5
   PubMed Web of Science ®Google Scholar
• Suttorp M, Bornhauser M, Metzler M, Millot F, Schleyer E. Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert Rev Clin Pharmacol. 2018;11(3):219–231. doi:10.1080/17512433.2018.1398644
   PubMed Web of Science ®Google Scholar
• Hijiya N, Maschan A, Rizzari C, et al. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Adv. 2021;5(14):2925–2934. doi:10.1182/bloodadvances.2020003759
   PubMed Web of Science ®Google Scholar
• SPRYCEL (dasatinib). Prescribing information. Bristol Myers Squibb; 2021.
   Google Scholar
• GLEEVAC (imatinib mesylate). Prescribing information. Novartis; 2020.
   Google Scholar
• Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, et al. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968. doi:10.1016/j.blre.2022.100968
   PubMed Web of Science ®Google Scholar